Australia adds class-wide GLP-1 eye warnings as US Ozempic label stays unchanged

Australia's Therapeutic Goods Administration is adding class-wide warnings about rare severe eye disorders to the labels of marketed GLP-1 receptor agonists and advising prompt medical attention for sudden vision changes, according to a Medicines Safety Update published July 23, 2026 ^[1][2].

The update is titled "GLP-1 RAs and rare vision disorder" and states that non-arteritic anterior ischemic optic neuropathy, or NAION, warnings will be added in Australia ^[2]. The action covers the drug class rather than one product ^[1].

Other regulators moved earlier. The European Medicines Agency concluded in 2025 that NAION should be listed as a very rare side effect of semaglutide medicines — Ozempic, Wegovy and Rybelsus — and estimated roughly one additional NAION case per 10,000 person-years of treatment, with epidemiologic estimates near a two-fold relative increase in adults with type 2 diabetes ^[1]. The TGA update lists earlier semaglutide-NAION communications from the UK's Medicines and Healthcare products Regulatory Agency and the World Health Organization ^[2].

The United States has taken a different path. The current Ozempic prescribing information, revised in May 2026, still does not include warnings about NAION or other eye side effects, according to an update on litigation over the drug ^[2]. No FDA action on the Ozempic label was announced in that update ^[2].

Two different eye problems

NAION is damage to the optic nerve from inadequate blood flow. It can cause sudden, usually painless vision loss or a new visual-field defect ^[1]. Diabetic retinopathy involves the retinal blood vessels and can temporarily worsen when glucose improves rapidly in some patients who already have the disease ^[1].

A 2026 systematic review found retinal findings across GLP-1 studies inconsistent. Apart from the SUSTAIN-6 signal, randomized trials generally did not show increased retinopathy progression, and observational studies were heterogeneous ^[1]. SUSTAIN-6 reported more diabetic retinopathy complications with semaglutide than placebo in a high-risk diabetes population, a result often read in the context of rapid HbA1c improvement and existing retinopathy ^[1].

Lawsuits over vision loss from NAION are being filed in the United States against Novo Nordisk, the maker of Ozempic, alleging failure to include NAION warnings ^[2]. The same update notes that because the label carries no NAION warning, prescribing doctors are not being named in those cases ^[2].

Why it matters for patients

Warnings can differ by country and by product, so information on an Australian label may not appear on a US one ^[1]. US patients are directed to current FDA labeling and clinician guidance ^[1].

NAION remains rare. The EMA's figure of about one extra case per 10,000 person-years is an estimated excess risk from that review, not a prediction for an individual patient and not proof that every GLP-1 product carries the same risk ^[1]. The agency also described relative-risk estimates near two-fold in adults with type 2 diabetes ^[1].

Sudden loss of vision, a dark curtain, a new missing area in the visual field, a marked change in one eye, flashes with many new floaters, or rapidly worsening eyesight are described as needing urgent evaluation rather than a routine appointment ^[1]. Diagnosis requires an eye professional; symptoms alone cannot distinguish NAION from retinopathy, retinal detachment, vascular occlusion, glaucoma or another cause ^[1].

No universal extra screening schedule has been established for every GLP-1 patient solely because of the prescription, according to the clinical guidance reviewed ^[1]. Coordinated eye care is described as more likely to be useful for people who already have diabetic retinopathy, prior retinal treatment, previous NAION, substantial vascular risk or an anticipated rapid improvement in markedly elevated glucose ^[1]. Patients with diabetes are advised to continue guideline-based retinal screening regardless of medication choice ^[1].

Whether treatment is stopped depends on the symptom and the diagnosis. Regulatory guidance may advise stopping a medicine when NAION is confirmed, while other visual complaints may call for a different response; abruptly stopping treatment can affect glucose or weight management, so the guidance describes urgent evaluation for urgent symptoms followed by a coordinated decision with the prescriber ^[1].

What happens next

Australia's update took effect with the July 23, 2026 notice ^[2]. Whether the FDA adds a NAION warning to Ozempic or other GLP-1 labels in the United States has not been reported ^[2].